The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
High Resistance of Plasmodium falciparum to Sulphadoxine/Pyrimethamine in Northern Tanzania and the Emergence of dhps Resistance Mutation at Codon 581
Open accessAbstract
BACKGROUND: Sulphadoxine-pyrimethamine (SP) a widely used treatment for uncomplicated malaria and recommended for intermittent preventive treatment of malaria in pregnancy, is being investigated for intermittent preventive treatment of malaria in infants (IPTi). High levels of drug resistance to SP have been reported from north-eastern Tanzania associated with mutations in parasite genes. This study compared the in vivo efficacy of SP in symptomatic 6-59 month children with uncomplicated malaria and in asymptomatic 2-10 month old infants. METHODOLOGY AND PRINCIPAL FINDINGS: An open label single arm (SP) standard 28 day in vivo WHO antimalarial efficacy protocol was used in 6 to 59 months old symptomatic children and a modified protocol used in 2 to 10 months old asymptomatic infants. Enrolment was stopped early (87 in the symptomatic and 25 in the asymptomatic studies) due to the high failure rate. Molecular markers were examined for recrudescence, re-infection and markers of drug resistance and a review of literature of studies looking for the 581G dhps mutation was carried out. In symptomatic children PCR-corrected early treatment failure was 38.8% (95% CI 26.8-50.8) and total failures by day 28 were 82.2% (95% CI 72.5-92.0). There was no significant difference in treatment failures between asymptomatic and symptomatic children. 96% of samples carried parasites with mutations at codons 51, 59 and 108 in the dhfr gene and 63% carried a double mutation at codons 437 and 540. 55% carried a third mutation with the addition of a mutation at codon 581 in the dhps gene. This triple: triple haplotype maybe associated with earlier treatment failure. CONCLUSION: In northern Tanzania SP is a failed drug for treatment and its utility for prophylaxis is doubtful. The study found a new combination of parasite mutations that maybe associated with increased and earlier failure. TRIAL REGISTRATION: ClinicalTrials.gov NCT00361114.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brooks, D. R., Wang, P., Read, M., Watkins, W. M., Sims, P. F. G., & Hyde, J. E. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.00397.x · Cited by 369
O. ter Kuile, F., van Eijk, A. M., & Filler, S. J. (2007) · JAMA · doi:10.1001/jama.297.23.2603 · Cited by 355
Peters, P. J., Thigpen, M. C., Parise, M. E., & Newman, R. D. (2007) · Drug Safety · doi:10.2165/00002018-200730060-00003 · Cited by 174
Cited by
Artemisinin resistance: current status and scenarios for containment
Dondorp, A. M., Yeung, S., White, L., Nguon, C., Day, N. P. J., Socheat, D., & von Seidlein, L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2331 · Cited by 645
Haldar, K., Bhattacharjee, S., & Safeukui, I. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.161 · Cited by 431
Malaria medicines: a glass half full?
Wells, T. N. C., van Huijsduijnen, R. H., & Van Voorhis, W. C. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4573 · Cited by 430
Kayentao, K., Garner, P., Maria van Eijk, A., Naidoo, I., Roper, C., Mulokozi, A., MacArthur, J. R., Luntamo, M., Ashorn, P., Doumbo, O. K., et al. (2013) · JAMA · doi:10.1001/jama.2012.216231 · Cited by 298
Self-citationAntimalarial drug resistance in Africa: the calm before the storm?
Conrad, M. D., & Rosenthal, P. J. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30261-0 · Cited by 255
Metadata
- Authors
- Gesase, S., Gosling, R. D., Hashim, R., Ord, R., Naidoo, I., Madebe, R., Mosha, J. F., Joho, A., Mandia, V., Mrema, H., Mapunda, E., Savael, Z., Lemnge, M., Mosha, F. W., Greenwood, B., Roper, C., & Chandramohan, D.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-02-24
- Volume
- 4
- Issue
- 2
- Pages
- e4569
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2048102298
- Cited by
- 169
- References
- 3
- FWCI
- 10.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.